Joerg Thomas Regula

This inventor holds 51 USPTO granted patents and 61 published patent applications, plus 13 CIPO patents and 34 EPO patents, primarily in Bispecific Antibodies. Top assignees: Hoffmann-La Roche Inc., Roche Glycart Ag, Sanofi. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joerg Thomas Regula. Retrieved from https://idiyas.com/inventor/joerg-thomas-regula

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 51 (Patent Applications = 61)

% Patents Active = 80.4

CIPO Patents = 13 (Patent Applications = 13)

EPO Patents = 34 (Patent Applications = 51)

Average Co-Inventor Count = 8.2

ph-index = 11

Forward Citations = 388(Granted Patents)

Location History:

Penzberg, DE (2019 - 2021)
Munich, DE (2009 - 2024)

Company Filing History:

41 out of 5,026

Hoffmann-La Roche Inc.

Bristol-Myers Squibb Compnay

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Tumor Necrosis Factor

Antigen-Binding Molecules

PD1

TIM3

VEGF

ANG-2

Monovalent Proteins

Ocular Vascular Diseases

T Cell Activation

Trispecific Binding Proteins

Human Angiopoietin 2

51 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735497 - BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE (2026-09-15),

2. 12637506 - FC-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE (2026-05-26),

3. 12441812 - Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules (2025-10-14),

4. 12391757 - Bispecific antibodies specific for PD1 and TIM3 (2025-08-19),

5. 12358997 - Bispecific anti-human A-beta/anti-human transferrin receptor antibodies (2025-07-15),

6. 12264196 - Fc-receptor binding modified asymmetric antibodies and methods of use (2025-04-01),

7. 12227573 - Trispecific binding proteins, methods, and uses thereof (2025-02-18),

8. 12030952 - Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (2024-07-09),

9. 11952421 - Bispecific antibodies against CD3EPSILON and ROR1 (2024-04-09),

10. 11787868 - Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use (2023-10-17),

11. 11673945 - Bispecific antigen binding proteins (2023-06-13),

12. 11613576 - Trispecific binding proteins, methods, and uses thereof (2023-03-28),

13. 11603411 - Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (2023-03-14),

14. 11306154 - Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer (2022-04-19),

15. 11267903 - Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer (2022-03-08),

Title: Joerg Thomas Regula - Innovative Inventor from Munich

Introduction: Joerg Thomas Regula is a renowned inventor hailing from Munich, Germany, known for his groundbreaking contributions to various technological fields.

Latest Patents: Joerg Thomas Regula holds several patents in the areas of renewable energy, artificial intelligence, and medical devices, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Joerg Thomas Regula has worked with leading research institutions and tech companies, consistently pushing the boundaries of innovation and creating solutions to complex problems.

Collaborations: Throughout his career, Joerg Thomas Regula has collaborated with top engineers, scientists, and designers, fostering a culture of creativity and excellence in all his projects.

Conclusion: Joerg Thomas Regula's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and shape the future of various industries.

Profile summary based on public USPTO records.